drugset / Trial / NCT01774851

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

NCT01774851

Phase 2 Terminated 84 enrolled Merrimack Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone

Timeline

Start
2013-01
Primary completion
2015-07
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MM-111 Unknown Intravenous
Background Paclitaxel Small molecule Intravenous
Background Trastuzumab Monoclonal antibody Intravenous